Form 4: Cara Therapeutics Executive Sells Shares to Cover Tax Obligations

Scott Terrillion, a Cara Therapeutics officer, sold 3,293 shares of common stock on February 29, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• On February 29, 2024, Scott Terrillion, Secretary, Chief Compliance Officer, and General Counsel of Cara Therapeutics, Inc., sold 3,293 shares of common stock at a price of $0.89 per share.
• The sale was executed under a pre-arranged 'sell to cover' arrangement adopted on September 7, 2018, to satisfy tax withholding obligations triggered by the vesting of restricted stock units.
• Following the transaction, Terrillion directly owns 91,000 shares of Cara Therapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing relates to a routine stock sale for tax purposes under a pre-existing plan, with no indication of significant positive or negative implications for the company.

Industry Context

This is a routine Form 4 filing, indicating an insider transaction. Such filings are common and provide transparency into the trading activities of company insiders. The use of a 10b5-1 plan suggests the transaction was pre-planned and not based on current market information.

Stakeholder Impact

• The sale of shares by an officer could have a minor, short-term impact on shareholder sentiment, but is unlikely to have a significant long-term effect given the reason for the sale.

Key Dates